Search Results
Sep 02, 2026, 04:18 ET Mazda publica los resultados de ventas del mes de agosto
para el CX-70 MHEVLas mejores ventas en un mes de agosto de la historia para el Mazda3 SedánMazda Canada, Inc. (MCI) ha comunicado que las ventas de agosto ascendieron a 7,592 vehículos, lo que supone un descenso del 8.2 % con respecto a agosto del año pasado. Las
More news about: Mazda North American Operations
Sep 01, 2026, 11:09 ET Mazda Reports August Sales Results
Best-ever August sales for CX-70 MHEVBest-ever August sales for Mazda3 SedanMazda Canada, Inc., (MCI) reported August sales of 7,592 vehicles, a decrease of 8.2 percent compared to August last year. Year-to-date sales totaled 49,694 vehicles sold; a
More news about: Mazda North American Operations
Sep 01, 2026, 01:25 ET Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®
issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible patients in Canada with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (early AD). The final recommendation follows a reconsideration by CDA-AMC and represents an important
More news about: BioArctic
Sep 01, 2026, 01:21 ET Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®
issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible patients in Canada with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (early AD). The final recommendation follows a reconsideration by CDA-AMC and represents an important
More news about: BioArctic
Aug 24, 2026, 08:43 ET Leqembi Iqlik® for initiation treatment launched in the US
www.bioarctic.com.[1] Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease, is collectively referred to as early Alzheimer's disease.This information was brought to you by
More news about: BioArctic
Aug 24, 2026, 08:39 ET Leqembi Iqlik® for initiation treatment launched in the US
www.bioarctic.com.[1] Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease, is collectively referred to as early Alzheimer's disease.This information was brought to you by
More news about: BioArctic
Aug 24, 2026, 08:00 ET LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
available in the U.S. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to as early AD. MCI due to AD is the earliest symptomatic stage of AD and can appear with subtle symptoms such as forgetfulness, confusion,
More news about: Eisai Inc.
Aug 14, 2026, 08:30 ET Sleep as a Window into Early Stages of Alzheimer's Pathophysiology: Implications for Clinical Development, Upcoming Webinar Hosted by Xtalks
accumulation itself. This webinar explores how sleep EEG can support earlier detection of Alzheimer's pathophysiology and inform AD/Mild Cognitive Impairment (MCI) trial design.
More news about: Xtalks
Aug 07, 2026, 10:57 ET Renew Biotechnologies Publishes Peer-Reviewed Research Advancing Cell-Type-Associated Biomarkers of Neurodegeneration
training of cell-type-associated methylation classifiers, and their application to plasma samples from individuals with AD, mild cognitive impairment (MCI), PD, ALS, and healthy controls. Across 137 blood samples, the proof-of-concept study identified disease-associated cfDNA signatures corresponding to
More news about: Renew Biotechnologies
Jul 16, 2026, 16:57 ET Diamond Transportation Expands Charter Bus Fleet, Strengthening Its Position as Arizona's Nationwide Motorcoach and Corporate Transportation Leader
Arizona-headquartered nationwide charter bus, motorcoach, and corporate transportation company, today announced another major fleet expansion with the addition of MCI luxury motorcoaches and executive Mercedes-Benz Sprinter party buses. The investment reflects the company's ongoing commitment to continuously
More news about: Diamond Transportation
Jul 16, 2026, 03:22 ET Cumulus Neuroscience präsentiert auf der AAIC-Jahrestagung 2026 Daten, die zeigen, dass eine zweiminütige digitale Aufgabe die klinischen Referenzwerte für die Vorauswahl bei Alzheimer-Studien erreicht oder übertrifft
tabletbasierte „Symbol Swap"-Aufgabe der NeuLogiq®-Plattform eine klinisch aussagekräftige Unterscheidung zwischen Kontrollpersonen, Personen mit MCI und Personen mit Alzheimer-Demenz und erkannte durch Blutbiomarker definierte pathologische Veränderungen – auch bei klinisch unauffälligen Personen
More news about: Cumulus Neuroscience
Jul 15, 2026, 09:54 ET Cumulus Neuroscience présente, lors du congrès annuel de l'AAIC 2026, des données montrant qu'une tâche numérique de deux minutes atteint ou dépasse les critères de référence cliniques en matière de pré-sélection des participants à un essai clinique sur la maladie d'Alzheimer.
plateforme NeuLogiq®, a permis d'établir une distinction cliniquement significative entre les groupes témoins, ceux atteints de troubles cognitifs légers (MCI) et ceux atteints de démence de type Alzheimer, et a détecté une pathologie définie par des biomarqueurs sanguins — y compris chez des individus cliniquement
More news about: Cumulus Neuroscience
Jul 15, 2026, 05:11 ET Cumulus Neuroscience Presents Data at AAIC 2026 Annual Meeting Showing a Two-Minute Digital Task Matches or Outperforms Clinical Benchmarks for Alzheimer's Trial Pre-enrichment
independent studies, the NeuLogiq® Platform two-minute tablet-based Symbol Swap task delivered clinically meaningful discrimination between control, MCI and Alzheimer's dementia groups and detected blood-biomarker-defined pathology — including in clinically normal individuals — with accuracy matching
More news about: Cumulus Neuroscience
Jul 15, 2026, 05:00 ET Cumulus Neuroscience Presents Data at AAIC 2026 Annual Meeting Showing a Two-Minute Digital Task Matches or Outperforms Clinical Benchmarks for Alzheimer's Trial Pre-enrichment
independent studies, the NeuLogiq® Platform two-minute tablet-based Symbol Swap task delivered clinically meaningful discrimination between control, MCI and Alzheimer's dementia groups and detected blood-biomarker-defined pathology — including in clinically normal individuals — with accuracy matching
More news about: Cumulus Neuroscience
Jul 15, 2026, 00:01 ET BLOOD TEST MAY HELP PREDICT RISK OF COGNITIVE DECLINE DUE TO ALZHEIMER'S A DECADE BEFORE SYMPTOMS APPEAR
healthy older adults with very high p-tau217 had an approximately 78% risk of developing cognitive impairment (defined as mild cognitive impairment or MCI, dementia or a consecutive clinical dementia rating or CDR, of 0.5) over 10 years, and about a 1-in-3 chance within five years. Even in those with slightly
More news about: Alzheimer’s Association
Jul 14, 2026, 11:41 ET More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
disease stage (MCI due to AD or mild AD dementia) from baseline throughout the course of Leqembi treatment. - Improvement: Patient transitioning from mild AD dementia at baseline to MCI due to AD over the course of Leqembi treatment. - Progression: Patient advancing from MCI at baseline
More news about: BioArctic
Jul 14, 2026, 11:39 ET More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
disease stage (MCI due to AD or mild AD dementia) from baseline throughout the course of Leqembi treatment. - Improvement: Patient transitioning from mild AD dementia at baseline to MCI due to AD over the course of Leqembi treatment. - Progression: Patient advancing from MCI at baseline
More news about: BioArctic
Jul 14, 2026, 11:15 ET LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
disease stage (MCI due to AD or mild AD dementia) from baseline throughout the course of LEQEMBI treatment.Improvement: Patient transitioning from mild AD dementia at baseline to MCI due to AD over the course of LEQEMBI treatment.Progression: Patient advancing from MCI at baseline to
More news about: Eisai Inc.
Jul 14, 2026, 00:01 ET ALZHEIMER'S BLOOD TEST COULD BRING HIGHLY ACCURATE DIAGNOSIS INTO EVERYDAY CLINICAL CARE
suggests there is great clinical utility for this test."The interim results from the study included 1,310 patients with mild cognitive impairment (MCI) or dementia in Sweden, including 927 evaluated by specialists and 383 evaluated in primary care. The patients seen in primary care were also independently
More news about: Alzheimer’s Association
Jul 13, 2026, 22:42 ET FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
convenience.Leqembi is indicated in the US for the treatment of adults with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease, collectively referred to as early Alzheimer's disease. MCI due to Alzheimer's disease represents the earliest symptomatic stage of the disease and may be associated
More news about: BioArctic
Jul 13, 2026, 22:37 ET FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
convenience.Leqembi is indicated in the US for the treatment of adults with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease, collectively referred to as early Alzheimer's disease. MCI due to Alzheimer's disease represents the earliest symptomatic stage of the disease and may be associated
More news about: BioArctic
Jul 13, 2026, 17:36 ET FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
administration.LEQEMBI is indicated in the United States for adults with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease, collectively referred to as early Alzheimer's disease. MCI due to AD is the earliest symptomatic stage of Alzheimer's disease and can appear with subtle symptoms
More news about: Eisai Inc.
Jul 13, 2026, 00:01 ET ALZHEIMER'S ASSOCIATION LAUNCHES "PROTECT-COG" STUDY TO TEST U.S. POINTER LIFESTYLE AND GLP-1 OR SIMILAR DRUG TO CUT RISK OF COGNITIVE DECLINE
with a metabolism-targeting drug, such as a GLP-1 agonist, can further reduce the risk of cognitive decline, mild cognitive impairment (MCI), and dementia in at-risk older adults. The $100 million effort was announced today for the first time at the
More news about: Alzheimer’s Association
Jul 12, 2026, 17:00 ET Study: "Physical Therapy for the Brain" Delivered by Telephone Shows Outcomes Meeting or Exceeding National In-Person Benchmarks
conducted with researchers at the University of Massachusetts Amherst, analyzed real-world outcomes for 141 older adults with mild cognitive impairment (MCI) or early-stage dementia treated under Medicare reimbursement. Just as physical therapy rebuilds strength and mobility, cognitive rehabilitation
More news about: Moneta Health
Jul 09, 2026, 13:16 ET /C O R R E C T I O N -- Eli Lilly and Company/
Kisunla® (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease. Warnings - Kisunla can cause Amyloid-Related Imaging Abnormalities or "ARIA." This is a
More news about: Eli Lilly and Company